UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) September 1, 2009
NOVAVAX, INC.
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-26770
|
|
22-2816046 |
(State or other jurisdiction
of incorporation or
organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| |
|
|
9920 Belward Campus Drive
Rockville, Maryland
(Address of principal executive offices)
|
|
20850
(Zip Code) |
Registrant’s
telephone number, including area code: (240) 268-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On September 1, 2009, Novavax, Inc. issued a press release announcing results from a Phase II human
clinical trial of its trivalent seasonal influenza virus-like particle vaccine candidate.
A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The
information furnished in this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not
be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| |
|
|
| Exhibits |
|
|
|
|
|
99.1
|
|
Press Release issued by Novavax, Inc., dated September 1, 2009. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized
| |
|
|
|
|
| |
Novavax, Inc.
(Registrant)
|
|
| September 1, 2009 |
By: |
/s/ Rahul Singhvi
|
|
| |
|
Name: |
Rahul Singhvi |
|
| |
|
Title: |
President and Chief Executive Officer |
|